Patents by Inventor Michael D. West

Michael D. West has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220160833
    Abstract: Aspects of the present invention include algorithms, methods and compositions related to the modulation of molecules regulating the mammalian transition from embryonic to fetal development. Methods and compositions for the use of such modulations to increase the regenerative potential in fetal and adult tissues otherwise incapable of scarless regeneration are also presented.
    Type: Application
    Filed: December 6, 2021
    Publication date: May 26, 2022
    Inventors: Michael D. West, Dana Larocca
  • Publication number: 20220112492
    Abstract: Aspects of the present invention include methods and compositions related to the modulation of molecules regulating the regenerative potential of cells and tissues in the embryonic state and the loss thereof in later fetal and adult stages of development. Said methods and compositions have uses in research in stern cell biology and in increasing regenerative potential in fetal and adult tissues otherwise incapable of regeneration.
    Type: Application
    Filed: February 17, 2021
    Publication date: April 14, 2022
    Inventors: Michael D. West, Karen Chapman, Hal Sternberg
  • Publication number: 20220088138
    Abstract: Aspects of the present invention include algorithms, methods and compositions related to the modulation of molecules regulating the mammalian transition from embryonic to fetal development. Methods and compositions for the use of such modulations to increase the regenerative potential in fetal and adult tissues otherwise incapable of scarless regeneration are also presented.
    Type: Application
    Filed: December 6, 2021
    Publication date: March 24, 2022
    Inventors: Michael D. West, Dana Larocca
  • Publication number: 20220088137
    Abstract: Aspects of the present invention include algorithms, methods and compositions related to the modulation of molecules regulating the mammalian transition from embryonic to fetal development. Methods and compositions for the use of such modulations to increase the regenerative potential in fetal and adult tissues otherwise incapable of scarless regeneration are also presented.
    Type: Application
    Filed: December 6, 2021
    Publication date: March 24, 2022
    Inventors: Michael D. West, Dana Larocca
  • Publication number: 20220090078
    Abstract: Aspects of the present invention include methods and compositions related to the modulation of molecules regulating the regenerative potential of cells and tissues in the embryonic state and the loss thereof in later fetal and adult stages of development. Said methods and compositions have uses in research in stem cell biology and in increasing regenerative potential in fetal and adult tissues otherwise incapable of regeneration.
    Type: Application
    Filed: December 6, 2021
    Publication date: March 24, 2022
    Inventors: Michael D. West, Karen Chapman, Hal Sternberg
  • Publication number: 20210180013
    Abstract: Aspects of the present invention include compositions and methods for discovering novel compositions and applying said compositions in treating medical conditions including aging, degenerative disease, wound treatment, and cancer through the modulation of molecular pathways regulating regeneration and senolysis by means of altering the embryonic-fetal and prenatal/postnatal transitional states of mammalian cells.
    Type: Application
    Filed: April 23, 2019
    Publication date: June 17, 2021
    Applicant: AgeX Therapeutics, Inc.
    Inventors: Michael D. West, Hal Stemberg
  • Publication number: 20210155895
    Abstract: Pluripotent stem cell-derived 3D retinal organoid compositions and methods of making using the same are disclosed.
    Type: Application
    Filed: April 4, 2017
    Publication date: May 27, 2021
    Applicant: LINEAGE CELL THERAPEUTICS, INC.
    Inventors: Igor Olegovich Nasonkin, Ratnesh Singh, Michael D. West, Hal Sterberg, David LAROCCA
  • Patent number: 10961531
    Abstract: Aspects of the present invention include methods and compositions related to the modulation of molecules regulating the regenerative potential of cells and tissues in the embryonic state and the loss thereof in later fetal and adult stages of development. Said methods and compositions have uses in research in stem cell biology and in increasing regenerative potential in fetal and adult tissues otherwise incapable of regeneration.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: March 30, 2021
    Assignee: AgeX Therapeutics, Inc.
    Inventors: Michael D. West, Karen Chapman, Hal Sternberg
  • Patent number: 10745752
    Abstract: The generation of clinical-grade cell-based therapies from human embryonic stein cells or cells reprogrammed to pluripotency from somatic cells, requires stringent quality controls to insure that the cells have long enough telomeres and resulting cellular lifespan to be clinically useful, and normal gene expression and genomic integrity so as to insure cells with a desired and reproducible phenotype and to reduce the risk of the malignant transformation of cells. Assays useful in identifying human embryonic stem cell lines and pluripotent cells resulting from the transcriptional reprogramming of somatic cells that have embryonic telomere length are described as well as quality control assays for screening genomic integrity in cells expanded and banked for therapeutic use, as well as assays to identify cells capable of abnormal immortalization.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: August 18, 2020
    Inventors: Michael D. West, Karen B. Chapman, Walter D. Funk
  • Publication number: 20200225213
    Abstract: A method of screening a composition for cardiotoxicity comprising contacting the composition with cardiomyocytes that have increased fatty acid oxidation and/or diminished glucose oxidation. The cardiomyocytes are preferably prepared by overexpression of COX7A1. The cardiomyocytes are preferably provided in a micropatterned co-culture to provide a mature functional hPSC-CM cardiotoxicity model.
    Type: Application
    Filed: January 7, 2020
    Publication date: July 16, 2020
    Applicant: AgeX Therapeutics, Inc.
    Inventors: Michael D. West, Jeffrey Janus
  • Publication number: 20200181567
    Abstract: This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease.
    Type: Application
    Filed: October 25, 2019
    Publication date: June 11, 2020
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Michael D. West, Karen B. Chapman, Roy Geoffrey Sargent
  • Publication number: 20200157505
    Abstract: Aspects of the present invention include methods and compositions related to the production and use of pluripotent stem cell-derived clonal embryonic progenitor cell types useful in the generation of cellular components of brown adipocyte tissue for research and therapy relating to applications in obesity, diabetes, and cardiovascular disease.
    Type: Application
    Filed: May 31, 2018
    Publication date: May 21, 2020
    Inventors: Michael D. West, Hal Sternberg
  • Patent number: 10501723
    Abstract: This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: December 10, 2019
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Michael D. West, Karen B. Chapman, Roy Geoffrey Sargent
  • Publication number: 20190225937
    Abstract: Methods for producing stem cell banks, preferably human, which optionally may be transgenic, e.g., comprised of homozygous MHC allele cell lines are provided. These cells are produced preferably from parthenogenic, IVF, or same-species or cross-species nuclear transfer embryos or by de-differentiation of somatic cells by cytoplasm transfer. Methods for using these stem cell banks for producing stem and differentiated cells for therapy, especially acute therapies, and for screening for drugs for disease treatment are also provided.
    Type: Application
    Filed: August 13, 2018
    Publication date: July 25, 2019
    Inventor: Michael D. West
  • Publication number: 20190218511
    Abstract: The invention provides methods, compositions and kits for the identification and enrichment of progenitor cell lines obtained from pluripotent stem cells.
    Type: Application
    Filed: January 22, 2019
    Publication date: July 18, 2019
    Inventors: Dana Larocca, Paola Bignone, Michael D. West, Evan Snyder
  • Publication number: 20190175691
    Abstract: Aspects of the present invention include algorithms, methods and compositions related to the modulation of molecules regulating the mammalian transition from embryonic to fetal development. Methods and compositions for the use of such modulations to increase the regenerative potential in fetal and adult tissues otherwise incapable of scarless regeneration are also presented.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Inventors: Michael D. West, Dana Larocca
  • Patent number: 10227561
    Abstract: The invention provides methods, compositions and kits for the identification and enrichment of progenitor cell lines obtained from pluripotent stem cells.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: March 12, 2019
    Assignees: Mandala Biosciences, LLC, BioTime, Inc., Sanford-Burnham Medical Research Institute
    Inventors: Dana Larocca, Paola Bignone, Michael D. West, Evan Snyder
  • Publication number: 20180170982
    Abstract: The vast differentiation potential of human embryonic and induced pluripotent stem cells, including their potential to cascade through all of the somatic cell lineages and to display the complete transcriptional regulatory network of human biology, has generated interest in deriving scalable, purified, and identified cell types and methods of discovering the precise structure of the human regulatory network. However, the innate capacity of pluripotent cells to display all these lineages is not necessarily reflected during their culture in vitro. The clonal isolation and propagation of progenitors greatly facilitates the generation of highly purified and indentified formulations for research and therapeutic purposes.
    Type: Application
    Filed: July 12, 2017
    Publication date: June 21, 2018
    Applicant: BioTime, Inc.
    Inventors: Michael D. West, Karen B. Chapman
  • Publication number: 20170335392
    Abstract: The generation of clinical-grade cell-based therapies from human embryonic stein cells or cells reprogrammed to pluripotency from somatic cells, requires stringent quality controls to insure that the cells have long enough telomeres and resulting cellular lifespan to be clinically useful, and normal gene expression and genomic integrity so as to insure cells with a desired and reproducible phenotype and to reduce the risk of the malignant transformation of cells. Assays useful in identifying human embryonic stem cell lines and pluripotent cells resulting from the transcriptional reprogramming of somatic cells that have embryonic telomere length are described as well as quality control assays for screening genomic integrity in cells expanded and banked for therapeutic use, as well as assays to identify cells capable of abnormal immortalization.
    Type: Application
    Filed: May 23, 2016
    Publication date: November 23, 2017
    Inventors: Michael D. West, Karen B. Chapman, Walter D. Funk
  • Patent number: 9732128
    Abstract: The vast differentiation potential of human embryonic and induced pluripotent stem cells, including their potential to cascade through all of the somatic cell lineages and to display the complete transcriptional regulatory network of human biology, has generated interest in deriving scalable, purified, and identified cell types and methods of discovering the precise structure of the human regulatory network. However, the innate capacity of pluripotent cells to display all these lineages is not necessarily reflected during their culture in vitro. The clonal isolation and propagation of progenitors greatly facilitates the generation of highly purified and identified formulations for research and therapeutic purposes.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: August 15, 2017
    Assignee: BioTime, Inc.
    Inventors: Michael D. West, Karen B. Chapman